Calprotectin Levels in Necrotizing Enterocolitis

A Comparative Study of Serum and Fecal Calprotectin Levels in Necrotizing Enterocolitis

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06693154

Enrollment

Registered

2024-11-18

Start date

2022-06-01

Completion date

2024-06-01

Last updated

2024-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Necrotising Enterocolitis Neonatal

Keywords

calprotectin, necrotising enterocolitis

Brief summary

Necrotizing enterocolitis (NEC) is a serious condition that can affect premature babies, leading to complications like intestinal damage and infection. In our study, we measured specific markers (called calprotectin) in blood and stool to understand how severe NEC is and predict outcomes. We found that these markers were higher in babies with more severe NEC (stage 3), especially in those who needed surgery or sadly did not survive. This information can help doctors detect NEC earlier, understand its severity, and make better decisions for treating affected babies.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

3 Days to 30 Days

Healthy volunteers

Inclusion criteria

before 32 weeks of gestation with a birth weight of ≤1500 grams

Exclusion criteria

Infants whose families did not provide consent and those with congenital anomalies were excluded.

Design outcomes

Primary

Measure	Time frame	Description
The predictive value of serum and fecal calprotectin levels in necrotising enterocolitis (NEC)	2 years	The predictive value of serum and fecal calprotectin levels in assessing NEC severity (stage 2 and stage 3), intestinal perforation, the need for surgery, and mortality.

Countries

Turkey (Türkiye)

Outcome results